Advancing cancer immunotherapy by targeting the unconventional
The Enara Bio™ purpose
Shining a light on Dark Antigen™ and T-cell biology to enable people to live free from the shadow of cancer.
Our mission is to advance novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific antigens designed to treat a broad patient population.
To achieve our mission, we have built a differentiated technology platform integrating bioinformatics, immunopeptidomics, metabolomics and immunology that enables us to interrogate both sides of the T-cell/cancer cell interface. Our growing team has the depth of expertise and breadth of experience to advance this exciting area of immuno-oncology for the benefit of broad groups of cancer patients and their families.
Read more about usWho we are
We are a diverse, experienced, and rapidly growing team driven by a common purpose and united by our shared values. The culture we have developed enables each of us to make an impact and deliver on our vision.
Latest News
-
Enara Bio’s presentation on development of an MR1-targeting T cell therapy from the 12th International CD1-MR1 EMBO Meeting
-
Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting
-
Enara Bio announces the appointment of T-cell therapy leader
Dr. Sophie Papa as Chief Medical Officer
Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) where she was a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist.
